Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;23(4):540-548.
doi: 10.1111/1756-185X.13800. Epub 2020 Feb 25.

Characteristics of diffuse large B-cell lymphoma in patients with primary Sjögren's syndrome

Vadim Romanovich Gorodetskiy  1 , Natalya Alexandrovna Probatova  2 , Vladimir Ivanovich Vasilyev  1
Affiliations

Characteristics of diffuse large B-cell lymphoma in patients with primary Sjögren's syndrome

Vadim Romanovich Gorodetskiy et al. Int J Rheum Dis. 2020 Apr.

Abstract

Aim: Patients with primary Sjögren's syndrome (pSS) have an increased risk of developing diffuse large B-cell lymphoma (DLBCL), which is an aggressive and heterogeneous non-Hodgkin lymphoma. This study aimed to characterize DLBCLs in patients with pSS.

Method: We identified 18 patients with DLBCL and pSS over a 22-year period. Based on the 2016 WHO guidelines, we characterized DLBCL based on immunohistochemical tests using a broad panel of antibodies, and an Epstein-Barr virus (EBV) test using in situ hybridization.

Results: The median time from initial pSS symptom onset to the DLBCL diagnosis was 20.5 years and the median time from the pSS diagnosis until the DLBCL diagnosis was 14 years. After the lymphoma diagnosis, the median overall survival was 3 months (range: 0-212 months) and the 5-year overall survival rate was 37.5%. Thirteen DLBCLs were re-classified as DLBCL, not otherwise specified (NOS) in nine cases; EBV-positive DLBCL, NOS in two cases; and T-cell/histiocyte-rich large B-cell lymphoma in two cases. Five cases of DLBCLs were not re-classified because their EBV status was unknown. The Hans algorithm, which uses a combination of staining for CD10, BCL6, and MUM1, was used to classify the DLBCLs into the germinal center B-cell (GCB) subtype for three cases and the non-GCB subtype for nine cases.

Conclusion: These results indicate that DLBCL tends to occur late in pSS cases and is mainly related to the non-GCB subtype of DLBCL.

Keywords: clinicopathological findings; diffuse large B-cell lymphoma; primary Sjögren's syndrome; prognostication; subtyping.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflicts of interest regarding the publication of this study.

Figures

Figure 1
Figure 1
Overall survival among the 18 patients with primary Sjögren's syndrome and diffuse large B‐cell lymphoma
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Anderson LA, Gadalla S, Morton LM, et al. Population‐based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer. 2009;125:398‐405. - PMC - PubMed
    1. Smedby EK, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non‐Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111:4029‐4038. - PMC - PubMed
    1. Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2017. ISBN‐13 (Print Book) 9789283244943.
    1. Shiboski SC, Shiboski CH, Criswell L, et al. American college of rheumatology classification criteria for Sjogren's syndrome: a data‐driven, expert consensus approach in the Sjogren's international collaborative clinical alliance cohort. Arthritis Care Res (Hoboken). 2012;64:475‐487. - PMC - PubMed
    1. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B‐cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275‐282. - PubMed

Substances